JP2006513187A5 - - Google Patents

Download PDF

Info

Publication number
JP2006513187A5
JP2006513187A5 JP2004562586A JP2004562586A JP2006513187A5 JP 2006513187 A5 JP2006513187 A5 JP 2006513187A5 JP 2004562586 A JP2004562586 A JP 2004562586A JP 2004562586 A JP2004562586 A JP 2004562586A JP 2006513187 A5 JP2006513187 A5 JP 2006513187A5
Authority
JP
Japan
Prior art keywords
composition
trkc
agonist antibody
antibody
trkc agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004562586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006513187A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/041367 external-priority patent/WO2004058190A2/en
Publication of JP2006513187A publication Critical patent/JP2006513187A/ja
Publication of JP2006513187A5 publication Critical patent/JP2006513187A5/ja
Pending legal-status Critical Current

Links

JP2004562586A 2002-12-23 2003-12-23 タキソール誘発性感覚性ニューロパシーを処置するための方法 Pending JP2006513187A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43614702P 2002-12-23 2002-12-23
PCT/US2003/041367 WO2004058190A2 (en) 2002-12-23 2003-12-23 Methods for treating taxol-induced sensory neuropathy

Publications (2)

Publication Number Publication Date
JP2006513187A JP2006513187A (ja) 2006-04-20
JP2006513187A5 true JP2006513187A5 (enExample) 2007-01-25

Family

ID=32682348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004562586A Pending JP2006513187A (ja) 2002-12-23 2003-12-23 タキソール誘発性感覚性ニューロパシーを処置するための方法

Country Status (10)

Country Link
US (1) US20050089521A1 (enExample)
EP (1) EP1581759B1 (enExample)
JP (1) JP2006513187A (enExample)
AT (1) ATE431157T1 (enExample)
AU (1) AU2003300397A1 (enExample)
CA (1) CA2511295A1 (enExample)
DE (1) DE60327655D1 (enExample)
ES (1) ES2326080T3 (enExample)
NZ (1) NZ540879A (enExample)
WO (1) WO2004058190A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004084836A2 (en) * 2003-03-20 2004-10-07 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
JP4503617B2 (ja) * 2003-12-23 2010-07-14 ライナット ニューロサイエンス コーポレイション アゴニスト抗trkC抗体および該抗体を用いる方法
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) * 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) * 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
DE69129154T2 (de) * 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
CA2175893C (en) * 1993-11-23 2010-06-22 Paul J. Godowski Protein tyrosine kinases named rse
JP3442784B2 (ja) * 1993-11-23 2003-09-02 ジェネンテク,インコーポレイテッド キナーゼ受容体活性化検定法
US5877016A (en) * 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6436908B1 (en) * 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU721942B2 (en) * 1996-06-25 2000-07-20 Cephalon, Inc. Use of K-252A derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
WO1999018792A1 (en) * 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
IL153375A0 (en) * 2000-06-22 2003-07-06 Genentech Inc Agonist anti-trk-c monoclonal antibodies
AU2001286930A1 (en) * 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
WO2004084836A2 (en) * 2003-03-20 2004-10-07 Rinat Neuroscience Corp. Methods for treating taxol-induced gut disorder
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos

Similar Documents

Publication Publication Date Title
LTPA2020001I1 (lt) Anti-IL-12 antikūnai, kompozicijos, būdai ir panaudojimas Krono patologijai gydyti
EE05309B1 (et) β-Amloidpeptiidi „ratundvad humaniseeritud antikehad, meetod nende valmistamiseks, nende kasutamine ja farmatseutiline kompositsioon
JP2007535490A5 (enExample)
EP2103628A4 (en) MONOCLONAL ANTI-CLAUDIN-3 ANTIBODY AND THE TREATMENT AND DIAGNOSIS OF CANCER AT ITS USE
EA030259B8 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
EA201300022A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
IL165193A (en) Humanized immunomodulatory monoclonal antibodies and use thereof for the treatment of neoplastic disease
ATE253912T1 (de) Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca
CR8698A (es) Anticuerpos monoclonales al factor de crecimiento de hepatocito
EP1516185A4 (en) Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
BR9609035A (pt) Anticorpos monoclonais de macaco específicos para formas primatizadas B7.1 e/ou B&.2 humanas composições farmacéuticas
CY2012019I1 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
DE60042648D1 (de) Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
DE60142500D1 (de) Humane monoklonale Antikörper gegen das kostimulatorische Signaltransduktionsmolekül AILIM und pharmazeutische Verwendungen davon
JP2007527865A5 (enExample)
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
BR0306808A (pt) Anticorpos monoclonais humanos contra cd30
EE200100667A (et) CD20 vastaste antikehade kasutamine transplantaadi peremehevastase reaktsiooni raviks
PL1648513T3 (pl) Zastosowanie przeciwciał z optymalizowaną adcc do leczenia pacjentów słabo odpowiadających na leczenie przeciwciałami
PT1299421E (pt) Anticorpos para a mcp-1 humana
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
NO20025302D0 (no) Aromatase-inhibitorer og monoklonale anti-HER2-antistoffer som antitumormidler
JP2004500325A5 (enExample)
DE60128452D1 (de) Monoklonale antikörper gegen den menschlichen ldl-rezeptor, deren herstellung und verwendung
ITRM20040586A1 (it) Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.